Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, includin...
Alivus Life Sciences reported revenue of 23.40 billion INR for fiscal year 2025, up 7.1% from fiscal year 2024, and net income of 4.86 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 6.02 billion INR, up 2.2% from a year before. outside India was its largest region in fiscal year 2025, with 52% of revenue. Its market capitalization was 165.15 billion INR as of October 12, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 12, 2026.
No profile data available.